Mild Cognitive Impairment as a Target for Drug Development

3/16/01


Click here to start


Table of Contents

Mild Cognitive Impairment as a Target for Drug Development

PPT Slide

Longitudinal Course of MCI

Syndrome of Mild Cognitive Impairment (MCI)

PPT Slide

Heterogeneous Syndrome vs. Specific Disease

PPT Slide

Clinical Criteria for MCI of AD Type

PPT Slide

PPT Slide

PPT Slide

PPT Slide

PPT Slide

MCI Trials As a Bridge to Prevention

Memory Screening in MCI Trials

Increasing MCI to AD Conversion Rate with Memory Impairment Criteria*

MCI Screening / Enrichment Tests

Outcome Measures for MCI Trials

Special Requirements for MCI Outcome Measures

Conclusions

Author: Steven H. Ferris, Ph.D.